Enlaza Therapeutics
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $161M
Overview
Engineering ultra-durable biologic drugs using a platform that irreversibly binds to disease targets.
Oncology
Technology Platform
The War-Lock™ platform engineers proteins with non-natural amino acids to form irreversible, covalent bonds with disease targets, aiming for ultra-durable activity.
Funding History
2Total raised:$161M
Series A$100M
Seed$61M
Opportunities
Potential to create best-in-class therapeutics for validated oncology targets and to drug previously intractable targets.
Risk Factors
Risk of off-target irreversible binding leading to toxicity, and unproven clinical translation of the platform.
Competitive Landscape
Competes with companies developing next-generation biologics, but its focus on irreversible covalent binding is a distinct approach.